Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Deferred Revenue (2018 - 2023)

Rocket Pharmaceuticals (RCKT) has disclosed Current Deferred Revenue for 6 consecutive years, with $597000.0 as the latest value for Q2 2023.

  • Quarterly Current Deferred Revenue changed 0.0% to $597000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $597000.0 through Jun 2023, changed 0.0% year-over-year, with the annual reading at $597000.0 for FY2022, 0.0% changed from the prior year.
  • Current Deferred Revenue hit $597000.0 in Q2 2023 for Rocket Pharmaceuticals, roughly flat from $597000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $597000.0 in Q1 2021 to a low of $541000.0 in Q1 2019.
  • Historically, Current Deferred Revenue has averaged $583000.0 across 5 years, with a median of $597000.0 in 2021.
  • Biggest five-year swings in Current Deferred Revenue: grew 5.46% in 2019 and later changed 0.0% in 2022.
  • Year by year, Current Deferred Revenue stood at $562000.0 in 2019, then grew by 4.98% to $590000.0 in 2020, then grew by 1.19% to $597000.0 in 2021, then changed by 0.0% to $597000.0 in 2022, then changed by 0.0% to $597000.0 in 2023.
  • Business Quant data shows Current Deferred Revenue for RCKT at $597000.0 in Q2 2023, $597000.0 in Q1 2023, and $597000.0 in Q4 2022.